Literature DB >> 33099213

The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites.

Lisa A Cannon-Albright1, Jeff Stevens2, Craig C Teerlink2, Neeraj Agarwal3.   

Abstract

HOXB13 p.Gly84Glu is recognized as a rare variant associated with increased risk for prostate cancer; risk association for other cancers is uncertain. This HOXB13 variant was originally reported in several 3-generation prostate cancer pedigrees and has been reported to be associated with increased risk for bladder and colorectal cancer and leukemia in GWAS. A HOXB13 pGly84Glu variant carrier was identified in a set of Utah individuals born more than 100 years ago who were members of high-risk cancer pedigrees. The proband carrier was diagnosed with colon cancer and is a member of a high-risk prostate cancer pedigree. The HOXB13 pGLY84Glu variant was assayed in other sampled relatives in the pedigree and was observed to segregate in relatives of the proband carrier in the extended pedigree; this pedigree showed significant excess of prostate cancer, cervical cancer, leukemia, colorectal cancer, and gastric cancer among descendants. Multiple additional variant carriers were identified, diagnosed with prostate, bladder, and colon cancers in the 5-generation high-risk cancer pedigree. This study shows the power and efficiency of a biorepository of samples with known genealogy from extended high-risk pedigrees for definition of cancer-associated risks. Association of HOXB13 p.Gly84Glu with risk of colon and bladder cancers in this extended pedigree confirms previous reports for risk association for both cancers.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Colon cancer; HOXB13; Pedigree; Prostate cancer; UPDB

Mesh:

Substances:

Year:  2020        PMID: 33099213      PMCID: PMC7710531          DOI: 10.1016/j.canep.2020.101834

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  15 in total

1.  Region-specific gastrointestinal Hox code during murine embryonal gut development.

Authors:  Yasuhiro Kawazoe; Tomohisa Sekimoto; Masatake Araki; Katsumasa Takagi; Kimi Araki; Ken-ichi Yamamura
Journal:  Dev Growth Differ       Date:  2002-02       Impact factor: 2.053

Review 2.  Utah family-based analysis: past, present and future.

Authors:  Lisa A Cannon Albright
Journal:  Hum Hered       Date:  2007-01-11       Impact factor: 0.444

3.  A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.

Authors:  Craig C Teerlink; Chad Huff; Jeff Stevens; Yao Yu; Sheri L Holmen; Mark R Silvis; Kirby Trombetti; Hua Zhao; Douglas Grossman; James M Farnham; Jingran Wen; Julio C Facelli; Alun Thomas; Markus Babst; Scott R Florell; Laurence Meyer; John J Zone; Sancy Leachman; Lisa A Cannon-Albright
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

4.  HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Authors:  Virpi H Laitinen; Tiina Wahlfors; Leena Saaristo; Tommi Rantapero; Liisa M Pelttari; Outi Kilpivaara; Satu-Leena Laasanen; Anne Kallioniemi; Heli Nevanlinna; Lauri Aaltonen; Robert L Vessella; Anssi Auvinen; Tapio Visakorpi; Teuvo L J Tammela; Johanna Schleutker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-04       Impact factor: 4.254

5.  Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer.

Authors:  Mohammad R Akbari; Laura N Anderson; Daniel D Buchanan; Mark Clendenning; Mark A Jenkins; Aung Ko Win; John L Hopper; Graham G Giles; Robert Nam; Steven Narod; Steven Gallinger; Sean P Cleary
Journal:  Cancer Epidemiol       Date:  2013-03-26       Impact factor: 2.984

6.  Germline mutations in HOXB13 and prostate-cancer risk.

Authors:  Charles M Ewing; Anna M Ray; Ethan M Lange; Kimberly A Zuhlke; Christiane M Robbins; Waibhav D Tembe; Kathleen E Wiley; Sarah D Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David W Craig; S Lilly Zheng; Patrick C Walsh; James E Montie; Jianfeng Xu; John D Carpten; William B Isaacs; Kathleen A Cooney
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

7.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

8.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

9.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.

Authors:  S V Tavtigian; J Simard; J Rommens; F Couch; D Shattuck-Eidens; S Neuhausen; S Merajver; S Thorlacius; K Offit; D Stoppa-Lyonnet; C Belanger; R Bell; S Berry; R Bogden; Q Chen; T Davis; M Dumont; C Frye; T Hattier; S Jammulapati; T Janecki; P Jiang; R Kehrer; J F Leblanc; J T Mitchell; J McArthur-Morrison; K Nguyen; Y Peng; C Samson; M Schroeder; S C Snyder; L Steele; M Stringfellow; C Stroup; B Swedlund; J Swense; D Teng; A Thomas; T Tran; M Tranchant; J Weaver-Feldhaus; A K Wong; H Shizuya; J E Eyfjord; L Cannon-Albright; M Tranchant; F Labrie; M H Skolnick; B Weber; A Kamb; D E Goldgar
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

10.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

Authors:  A Kamb; D Shattuck-Eidens; R Eeles; Q Liu; N A Gruis; W Ding; C Hussey; T Tran; Y Miki; J Weaver-Feldhaus
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

View more
  1 in total

1.  HOXB13 suppresses proliferation, migration and invasion, and promotes apoptosis of gastric cancer cells through transcriptional activation of VGLL4 to inhibit the involvement of TEAD4 in the Hippo signaling pathway.

Authors:  Hui Geng; Guangli Liu; Jiandong Hu; Jianchao Li; Dong Wang; Shenshan Zou; Xintao Xu
Journal:  Mol Med Rep       Date:  2021-08-13       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.